PD31-06 UPDATED LONG-TERM SURVIVAL AND SAFETY FROM A MULTI-CENTER, OPEN-LABEL, PIVOTAL PHASE 2 STUDY OF AZEDRA® IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA

INTRODUCTION AND OBJECTIVE:Pheochromocytoma/Paraganglioma (PPGL) are rare neuroendocrine tumors with a 5-yr survival rate as low as 12%. Effective treatment options for patients with advanced disea...